Thermo Fisher Scientific Inc (TMO)
Industry Diagnostics & Research
This stock can be held in an Investment ISA and an Investment Account
Sell
$559.57
Buy
$570.05
$-7.60 (-1.33%)
Prices updated at 17 Dec 2025, 21:10 EST
| Prices minimum 15 mins delay
Prices in USD
Thermo Fisher Scientific Inc is a healthcare company. It offers analytical instruments, laboratory equipment, software, services, consumables, reagents and chemicals.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 42,857m | 42,879m | |
| 17,100m | 17,702m | |
| 7,318m | 7,717m | |
| 17.08 | 18.00 | |
| 5,995m | 6,335m | |
| 11,079m | 11,535m | |
| Sales, General and administrative | 8,445m | 8,595m |
| Interest expenses | 1,375m | 1,390m |
| Provision for income taxes | 284m | 657m |
| Operating expenses | 9,782m | 9,985m |
| Income before taxes | 6,298m | 7,037m |
| Net income available to common shareholders | 5,995m | 6,335m |
| 15.52 | 16.58 | |
| Net interest income | -496m | -312m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | 15.45 | 16.53 |
| Free cash flow per share | 16.8386 | 20.2342 |
| Book value/share | 117.2334 | 128.6641 |
| Debt equity ratio | 0.669905 | 0.586085 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 24,589m | 22,137m |
| Current liabilities | 14,012m | 13,332m |
| Total capital | 78,043m | 78,646m |
| Total debt | 34,917m | 31,275m |
| Total equity | 46,735m | 49,585m |
| Total non current liabilities | - | - |
| Loans | 31,308m | 29,061m |
| Total assets | 98,726m | 97,321m |
| Total liabilities | - | - |
| Cash and cash equivalents | 8,077m | 4,009m |
| Common stock | 387m | 381m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 8,537m | 8,097m |
| Cash dividends paid | -523m | -583m |
| 6,927m | 7,267m | |
| Investments (gains) losses | -5,142m | -5,841m |
| 8,097m | 4,040m | |
| Net income | - | - |
| 8,406m | 8,667m | |
| -1,479m | -1,400m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.